


[CLAIMS]

1. A compound represented by the general formula (I-1):



{wherein, X and Y represent -CH= or a nitrogen atom, {provided that both X and Y do not represent -CH=, simultaneously}}, respectively,

Z represents an oxygen atom or a sulfur atom,

T represents a carbon atom or a nitrogen atom,

Ring A represents a 5 to 7-membered monocycle,

Ring B represents a 5 to 7-membered monocycle or a 8 to 10-membered bicycle,

L¹ represents a bond, -O-, -CONH-, -CO-, -CO₂-, -S-, -SO₂- or -SO-,

L² represents a bond, a C1-3 alkylene group, a C3-7 cycloalkylene group or a phenylene group,

R¹ represents a hydrogen atom, a halogen atom, a hydroxyl group, a cyano group, N(R^{1a})₂, {herein, the two R^{1a}s represent each independently a hydrogen atom or a C1-4 alkyl group}, a C1-4 alkyl group, a carboxy group, a C1-4 alkoxy carbonyl group, a C1-4 haloalkyl group, a

methyl-d₃ group, a C3-7 cycloalkyl group, a phenyl group or a 3 to 7-membered monocyclic non-aromatic heterocycle,

R^{2c} represents a hydrogen atom, a hydroxyl group, a halogen atom, an oxo group, a nitro group, a cyano group, a C1-4 alkoxy group or -CH₂NR^{2d}R^{2e} or NR^{2d}R^{2e}, {herein, R^{2d} is a hydrogen atom, a C1-4 alkyl group or R^{FR}, and R^{2e} represents a hydrogen atom},

m represents an integer of 0 or 1,

R³ represents a hydrogen atom, a halogen atom, a hydroxyl group, a C1-4 alkyl group, a C1-4 alkoxy group, a C1-4 haloalkyl group, a C1-4 haloalkoxy group or an amino group,

n represents an integer of 1 to 16, {herein, when n is 2 or more, the groups represented by a plurality of R³s may be the same or different},

R^{4a} represents a hydrogen atom, a C1-4 alkyl group, a carboxy group or R^{FR},

R⁵ represents a C1-4 alkyl group,

p represents an integer of 0 to 5, {herein, when p is 2 or more, the groups represented by a

plurality of R^5 s may be the same or different),



R^{6a} represents a hydrogen atom, a C1-4 alkyl group or R^{FR} ,

R^7 is a hydrogen atom, b represents the bonding position of Ring B, R^{FR} represents -
 $(CR^{Fb})_qOP(=O)(OR^{Fa})_{2-}$

5 -[wherein, R^{Fa} represents each independently a hydrogen atom, a C1-4 alkyl group, a C3-6 cycloalkyl group, $-(CH_2)_2OH$ or $-CH_2OCO_2CH(CH_3)_2$,

R^{Fb} represents a hydrogen atom or a methyl group, and q represents an integer of 1 or 2, (herein, the groups represented by a plurality of R^{Fb} s may be the same or different)-], provided that two or more of R^{2d} , R^{4a} and R^{6a} do not represent R^{FR} , simultaneously-],

10 wherein



wherein U represents a nitrogen atom or a carbon atom, herein when U represents a nitrogen atom, m represents 0, and when U represents a carbon atom, m represents 1,

15 W represents $-CR^3=$ or a nitrogen atom,

V represents $-CH=$ or a nitrogen atom, and when the formula (Ib-1) has a plurality of R^3 s, the groups represented by them may be the same or different, and other symbols represent the same meaning as those in this claim,

a pharmaceutically acceptable salt thereof or a solvate thereof.

20

2. The compound, the pharmaceutically acceptable salt thereof or the solvate thereof, according to claim 1, wherein Ring A is (a) a C5-6 monocyclic carbocycle or (b) a 5 to 6 membered monocyclic heterocycle containing 1 to 4 heteroatoms selected from an oxygen atom, a nitrogen atom and a sulfur atom.

25

~~3. The compound, the pharmaceutically acceptable salt thereof or the solvate thereof, according to claim 1 or 2, wherein Ring B is (a) a C5-6 monocyclic carbocycle or (b) a 5 to 6 membered monocyclic heterocycle containing 1 to 4 heteroatoms selected from an oxygen atom,~~

a nitrogen atom and a sulfur atom.

34. The compound, the pharmaceutically acceptable salt thereof or the solvate thereof, according to claim 1 or 3, wherein Ring A is (a) a benzene ring or (b) a 5 to 6-membered monocyclic aromatic heterocycle containing 1 to 4 heteroatoms selected from an oxygen atom, a nitrogen atom and a sulfur atom.


~~5. The compound, the pharmaceutically acceptable salt thereof or the solvate thereof, according to any one of claims 1, 2 and 4, wherein Ring B is (a) a benzene ring or (b) a 5 to 6-membered monocyclic aromatic heterocycle containing 1 to 4 heteroatoms selected from an oxygen atom, a nitrogen atom and a sulfur atom.~~

46. The compound, the pharmaceutically acceptable salt thereof or the solvate thereof, according to any one of claims 1, 3 and 5, wherein Ring A is a 5 to 6-membered monocyclic aromatic nitrogen-containing heterocycle containing 1 to 4 nitrogen atoms, without any other heteroatoms.


57. The compound, the pharmaceutically acceptable salt thereof or the solvate thereof, according to any one of claims 1 to 46, wherein Z is an oxygen atom.

68. The compound, the pharmaceutically acceptable salt thereof or the solvate thereof, according to any one of claims 1 to 57, wherein X is a nitrogen atom and Y is -CH=.

~~9. The compound, the pharmaceutically acceptable salt thereof or the solvate thereof, according to any one of claims 1 to 8, wherein~~




[wherein, the arrow is bound to the carbon atom represented by b in the general formula (I-1), and other symbols represent the same meanings as those in claim 1.] of the general formula (I-1) is the group represented by the formula (Ib-1):



[wherein, U represents a nitrogen atom or a carbon atom (herein, when U represents a nitrogen atom, m represents 0, and when U represents a carbon atom, m represents 1), W represents CR^3 or a nitrogen atom, V represents CH or a nitrogen atom, and when the formula (Ib-1) has a plurality of R^3 s, the groups represented by them may be the same or different, and other symbols represent the same meaning as those in claim 1.].

107. The compound, the pharmaceutically acceptable salt thereof, or the solvate thereof, according to claim 1, wherein the compound represented by the general formula (I-1) is the compound represented by the general formula (II-1):



[wherein, all symbols represent the same meanings as those of claims 1 and 9.].


118. The compound, the pharmaceutically acceptable salt thereof or the solvate thereof, according to any one of claims 1 to 107, wherein T is a nitrogen atom.

129. The compound, the pharmaceutically acceptable salt thereof or the solvate thereof, according to any one of claims 9 to 118, wherein U is a carbon atom.

1310. The compound, the pharmaceutically acceptable salt thereof or the solvate thereof, according to any one of claims 1 and 3, 5 and 7 to 129, wherein Ring A is pyrazole, triazole, tetrazole, oxazole, isoxazole, imidazole, thiazole or isothiazole.

1411. The compound, the pharmaceutically acceptable salt thereof or the solvate thereof, according to claim 1, wherein the compound represented by the general formula (I-1) is the

compound represented by the general formula (III-1):



{wherein, p_a represents an integer of 0 to 2, and other symbols represent the same meanings as those of claims 1 and 9.}

~~15~~12. The compound, the pharmaceutically acceptable salt thereof or the solvate thereof, according to any one of claims 1 to ~~14~~11, wherein L^2 is a bond or a C1-3 alkylene group.

~~16~~13. The compound, the pharmaceutically acceptable salt thereof or the solvate thereof, according to any one of claims 1 to ~~15~~12, wherein L^1 is -CONH- (provided that the left side of the group is bound to Ring B), -CO-, -CO₂-, -S-, -SO₂- or -SO-.

~~17~~14. The compound, the pharmaceutically acceptable salt thereof or the solvate thereof, according to any one of claims 1 to ~~16~~13; wherein R^1 is a hydrogen atom or a C1-4 alkyl group.

~~18~~15. The compound, the pharmaceutically acceptable salt thereof or the solvate thereof, according to any one of claims 1 to ~~17~~14, wherein R^{2c} is a nitro group or $NR^{2d}R^{2e}$.

~~19~~16. The compound, the pharmaceutically acceptable salt thereof or the solvate thereof, according to any one of claims 1 to ~~18~~15, wherein R^3 is a hydrogen atom, a halogen atom or a hydroxyl group.

~~20~~17. The compound, the pharmaceutically acceptable salt thereof or the solvate thereof, according to any one of claims 1 to ~~19~~16, wherein R^{4a} is a hydrogen atom or R^{FR} , and both of R^{2d} and R^{6a} are hydrogen atoms.

~~21~~19. The compound, the pharmaceutically acceptable salt thereof or the solvate thereof,

according to any one of claims 1 to ~~20~~17, wherein $-(CR^{Fb})_qOP(=O)(OR^{Fa})_2$ represented by R^{FR} is $-CH_2OP(=O)(OH)_2$, $-CH(CH_3)OP(=O)(OH)_2$ or $-CH_2OP(=O)(OH)(OCH_2OCO_2CH(CH_3)_2)$.

~~22~~20. The compound, the pharmaceutically acceptable salt thereof or the solvate thereof, according to any one of claims 1 to ~~24~~19, wherein p and pa are zero or 1.

~~23~~21. The compound, the pharmaceutically acceptable salt thereof or the solvate thereof, according to claim 1, wherein the compound represented by the general formula (I-1) is the compound selected from the group consisting of:

- 10 (1) 4-(4-amino-2-fluoro-5-methoxyphenyl)-7-(1*H*-pyrazol-4-yl)isoxazolo[5,4-*c*]pyridin-3-amine,
- (2) 4-(4-amino-2-fluoro-5-methoxyphenyl)-7-(1*H*-pyrazol-4-yl)isoxazolo[4,5-*c*]pyridin-3-amine,
- (3) 4-(4-amino-3-methoxyphenyl)-7-(1*H*-pyrazol-4-yl)isoxazolo[4,5-*c*]pyridin-3-amine,
- 15 (4) 4-(4-amino-2-fluoro-5-(methylthio)phenyl)-7-(1*H*-pyrazol-4-yl)isoxazolo[4,5-*c*]pyridin-3-amine,
- (5) 4-(4-amino-2-fluoro-5-(methoxy-*d*₃)phenyl)-7-(1*H*-pyrazol-4-yl)isoxazolo[4,5-*c*]pyridin-3-amine,
- (6) 4-(4-amino-2-fluoro-5-(methylsulfonyl)phenyl)-7-(1*H*-pyrazol-4-yl)isoxazolo[4,5-*c*]pyridin-3-amine,
- 20 (7) 4-(4-amino-5-(ethylthio)-2-fluorophenyl)-7-(1*H*-pyrazol-4-yl)isoxazolo[4,5-*c*]pyridin-3-amine,
- (8) 4-(4-amino-2-fluoro-5-(methylsulfinyl)phenyl)-7-(1*H*-pyrazol-4-yl)isoxazolo[4,5-*c*]pyridin-3-amine,
- 25 (9) 4-(4-amino-2-fluoro-3-methoxyphenyl)-7-(1*H*-pyrazol-4-yl)isoxazolo[4,5-*c*]pyridin-3-amine,
- (10) methyl 2-amino-5-(3-amino-7-(1*H*-pyrazol-4-yl)isoxazolo[4,5-*c*]pyridin-4-yl)-4-fluorobenzoate,
- (11) 2-amino-5-(3-amino-7-(1*H*-pyrazol-4-yl)isoxazolo[4,5-*c*]pyridin-4-yl)-4-fluorobenzoic acid,
- 30 (12) 2-amino-5-(3-amino-7-(1*H*-pyrazol-4-yl)isoxazolo[4,5-*c*]pyridin-4-yl)-4-fluorobenzamide,
- (13) 4-(4-amino-2-fluoro-5-methoxyphenyl)-7-(3-methyl-1*H*-pyrazol-4-yl)isoxazolo[4,5-

- c]pyridin-3-amine,
- (14) methyl 2-amino-5-(3-amino-7-(1-((phosphonooxy)methyl)-1*H*-pyrazol-4-yl)isoxazolo[4,5-*c*]pyridin-4-yl)-4-fluorobenzoate,
- (15) 1-(2-amino-5-(3-amino-7-(1*H*-pyrazol-4-yl)isoxazolo[4,5-*c*]pyridin-4-yl)-4-fluorophenyl)ethan-1-one,
- (16) 4-(4-amino-2-chloro-5-(methylthio)phenyl)-7-(1*H*-pyrazol-4-yl)isoxazolo[4,5-*c*]pyridin-3-amine,
- (17) ethyl 2-amino-5-(3-amino-7-(1*H*-pyrazol-4-yl)isoxazolo[4,5-*c*]pyridin-4-yl)-4-fluorobenzoate,
- (18) (4-(4-(5-acetyl-4-amino-2-fluorophenyl)-3-aminoisoxazolo[4,5-*c*]pyridin-7-yl)-1*H*-pyrazol-1-yl)methyl dihydrogen phosphate,
- (19) ethyl 2-amino-5-(3-amino-7-(1-((phosphonooxy)methyl)-1*H*-pyrazol-4-yl)isoxazolo[4,5-*c*]pyridin-4-yl)-4-fluorobenzoate,
- (20) 2-amino-5-(3-amino-7-(1*H*-pyrazol-4-yl)isoxazolo[4,5-*c*]pyridin-4-yl)-4-fluoro-*N*-methylbenzamide,
- (21) 1-(2-amino-5-(3-amino-7-(1*H*-pyrazol-4-yl)isoxazolo[4,5-*c*]pyridin-4-yl)-4-fluorophenyl)propan-1-one,
- (22) 2-amino-5-(3-amino-7-(1*H*-pyrazol-4-yl)isoxazolo[4,5-*c*]pyridin-4-yl)-*N*-ethyl-4-fluorobenzamide,
- (23) 1-(2-amino-5-(3-amino-7-(1*H*-pyrazol-4-yl)isoxazolo[4,5-*c*]pyridin-4-yl)phenyl)ethan-1-one,
- (24) methyl 2-amino-5-(3-amino-7-(1*H*-pyrazol-4-yl)isoxazolo[4,5-*c*]pyridin-4-yl)benzoate,
- (25) 2-amino-5-(3-amino-7-(1*H*-pyrazol-4-yl)isoxazolo[4,5-*c*]pyridin-4-yl)-*N*-propylbenzamide,
- (26) 1-(2-amino-5-(3-amino-7-(1*H*-pyrazol-4-yl)isoxazolo[4,5-*c*]pyridin-4-yl)-4-fluorophenyl)butan-1-one,
- (27) 2-amino-5-(3-amino-7-(1*H*-pyrazol-4-yl)isoxazolo[4,5-*c*]pyridin-4-yl)-4-fluoro-*N*-propylbenzamide,
- (28) 1-(2-amino-5-(3-amino-7-(1*H*-pyrazol-4-yl)isoxazolo[4,5-*c*]pyridin-4-yl)phenyl)butan-1-one,
- (29) 2-hydroxyethyl 2-amino-5-(3-amino-7-(1*H*-pyrazol-4-yl)isoxazolo[4,5-*c*]pyridin-4-yl)-4-fluorobenzoate,
- (30) 2-amino-5-(3-amino-7-(1*H*-pyrazol-4-yl)isoxazolo[4,5-*c*]pyridin-4-yl)benzamide,

- (31) 2-amino-5-(3-amino-7-(1*H*-pyrazol-4-yl)isoxazolo[4,5-*c*]pyridin-4-yl)-*N*-methylbenzamide,
- (32) (4-(3-amino-4-(4-amino-5-(ethylcarbamoyl)-2-fluorophenyl)isoxazolo[4,5-*c*]pyridin-7-yl)-1*H*-pyrazol-1-yl)methyl dihydrogen phosphate,
- 5 (33) 1-(2-amino-5-(3-amino-7-(1*H*-pyrazol-4-yl)isoxazolo[4,5-*c*]pyridin-4-yl)-4-hydroxyphenyl)ethan-1-one,
- (34) 2-amino-5-(3-amino-7-(1*H*-pyrazol-4-yl)isoxazolo[4,5-*c*]pyridin-4-yl)-*N*-ethylbenzamide,
- (35) 1-(2-amino-5-(3-amino-7-(1*H*-pyrazol-4-yl)isoxazolo[4,5-*c*]pyridin-4-yl)phenyl)propan-1-one,
- 10 (36) 2-amino-5-(3-amino-7-(1*H*-pyrazol-4-yl)isoxazolo[4,5-*c*]pyridin-4-yl)-4-chloro-*N*-ethylbenzamide,
- (37) (4-(3-amino-4-(4-amino-2-fluoro-5-(methylthio)phenyl)isoxazolo[4,5-*c*]pyridin-7-yl)-1*H*-pyrazol-1-yl)methyl dihydrogen phosphate,
- (38) (4-(3-amino-4-(4-amino-2-fluoro-5-propionylphenyl)isoxazolo[4,5-*c*]pyridin-7-yl)-1*H*-pyrazol-1-yl)methyl dihydrogen phosphate,
- 15 (39) (4-(4-(3-acetyl-4-aminophenyl)-3-aminoisoxazolo[4,5-*c*]pyridin-7-yl)-1*H*-pyrazol-1-yl)methyl dihydrogen phosphate,
- (40) 4-(2-fluoro-5-methoxy-4-nitrophenyl)-7-(1*H*-pyrazol-4-yl)isoxazolo[4,5-*c*]pyridin-3-amine,
- 20 (41) (4-(3-amino-4-(4-amino-2-fluoro-5-(methylsulfonyl)phenyl)isoxazolo[4,5-*c*]pyridin-7-yl)-1*H*-pyrazol-1-yl)methyl dihydrogen phosphate,
- (42) (4-(3-amino-4-(4-amino-5-(ethylcarbamoyl)-2-chlorophenyl)isoxazolo[4,5-*c*]pyridin-7-yl)-1*H*-pyrazol-1-yl)methyl dihydrogen phosphate,
- (43) 1-(2-amino-5-(3-amino-7-(1*H*-pyrazol-4-yl)isothiazolo[4,5-*c*]pyridin-4-yl)-4-fluorophenyl)ethan-1-one, and
- 25 (44) 4-(4-amino-2-fluoro-5-(trifluoromethyl)phenyl)-7-(1*H*-pyrazol-4-yl)isoxazolo[4,5-*c*]pyridin-3-amine.

2422. The compound, the pharmaceutically acceptable salt thereof or the solvate thereof, according to claim 1, wherein the compound represented by the general formula (I-1) is the compound selected from the group consisting of:

- (1) methyl 2-amino-5-(3-amino-7-(1-((phosphonooxy)methyl)-1*H*-pyrazol-4-yl)isoxazolo[4,5-*c*]pyridin-4-yl)-4-fluorobenzoate,

- (2) (4-(4-(5-acetyl-4-amino-2-fluorophenyl)-3-aminoisoxazolo[4,5-c]pyridin-7-yl)-1*H*-pyrazol-1-yl)methyl dihydrogen phosphate,
- (3) ethyl 2-amino-5-(3-amino-7-(1-((phosphonooxy)methyl)-1*H*-pyrazol-4-yl)isoxazolo[4,5-c]pyridin-4-yl)-4-fluorobenzoate,
- 5 (4) (4-(3-amino-4-(4-amino-5-(ethylcarbamoyl)-2-fluorophenyl)isoxazolo[4,5-c]pyridin-7-yl)-1*H*-pyrazol-1-yl)methyl dihydrogen phosphate,
- (5) (4-(3-amino-4-(4-amino-2-fluoro-5-(methylthio)phenyl)isoxazolo[4,5-c]pyridin-7-yl)-1*H*-pyrazol-1-yl)methyl dihydrogen phosphate,
- (6) (4-(3-amino-4-(4-amino-2-fluoro-5-propionylphenyl)isoxazolo[4,5-c]pyridin-7-yl)-1*H*-pyrazol-1-yl)methyl dihydrogen phosphate,
- 10 (7) (4-(4-(3-acetyl-4-aminophenyl)-3-aminoisoxazolo[4,5-c]pyridin-7-yl)-1*H*-pyrazol-1-yl)methyl dihydrogen phosphate,
- (8) (4-(3-amino-4-(4-amino-2-fluoro-5-(methylsulfonyl)phenyl)isoxazolo[4,5-c]pyridin-7-yl)-1*H*-pyrazol-1-yl)methyl dihydrogen phosphate, and
- 15 (9) (4-(3-amino-4-(4-amino-5-(ethylcarbamoyl)-2-chlorophenyl)isoxazolo[4,5-c]pyridin-7-yl)-1*H*-pyrazol-1-yl)methyl dihydrogen phosphate.

2523. The pharmaceutically acceptable salt of the compound or the solvate thereof, according to any one of claims 1 to 2422, wherein the pharmaceutically acceptable salt of the compound according to any one of claims 1 to 24 is an alkali metal salt.

20

2624. The solvate of the compound or the pharmaceutically acceptable salt thereof, according to any one of claims 1 to 2523, wherein the solvate of the compound or the pharmaceutically acceptable salt thereof according to any one of claims 1 to 25-23 is a hydrate.

25

2725. A pharmaceutical composition comprising the compound represented by the general formula (I-1) or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.

2826. Use of an agent comprising the compound represented by the general formula (I-1) or a pharmaceutically acceptable salt thereof, as an active ingredient in the manufacture of a medicament for suppressing the progression of, suppressing the recurrence of and/or treating cancer.

30

~~29~~27. The use according to claim ~~28~~26, wherein the cancer is solid cancer or blood cancer.

~~30~~28. The use according to claim ~~29~~26, wherein the solid cancer is one or more cancers
 5 selected from malignant melanoma, non-small cell lung cancer, small cell lung cancer, head
 and neck cancer, renal cell cancer, breast cancer, ovarian cancer, ovarian clear cell
 adenocarcinoma, nasopharyngeal cancer, uterine cancer, anal cancer, colorectal cancer, rectal
 cancer, colon cancer, hepatocellular carcinoma, esophageal cancer, gastric cancer,
 esophagogastric junction cancer, pancreatic cancer, urine urothelial cancer, prostate cancer,
 10 fallopian tube cancer, primary peritoneal cancer, malignant pleural mesothelioma, gallbladder
 cancer, bile duct cancer, biliary tract cancer, skin cancer, testicular cancer (germ cell tumor),
 vaginal cancer, vulvar cancer, penile cancer, small intestine cancer, endocrine system cancer,
 thyroid cancer, parathyroid cancer, adrenal carcinoma, spinal tumor, neuroblastoma,
 medulloblastoma, ocular retinoblastoma, neuroendocrine tumor, brain tumor and squamous cell
 15 carcinoma.

~~31~~29. The use according to claim ~~29~~27, wherein the solid cancer is bone/soft tissue sarcoma
 or Kaposi's sarcoma.

~~32~~30. The use according to claim ~~29~~27, wherein the blood cancer is one or more cancers
 20 selected from multiple myeloma, malignant lymphoma, leukemia, central nervous system
 malignant lymphoma, myelodysplastic syndromes and myeloproliferative syndromes.

~~33~~31. The use according to any one of claims ~~28~~26 to ~~32~~30, wherein the medicament is to be
 25 administered in combination with one or more kinds of other anti-cancer drugs.

~~34~~32. The use according to claim ~~33~~31, wherein the other anti-cancer drug is a cancer
 immunotherapeutic drug.

~~35~~33. The use according to claim ~~34~~32, wherein the cancer immunotherapeutic drug is an
 30 anti-PD-1 antibody or an anti-PD-L1 antibody.

~~36~~34. A STING agonistic agent comprising the compound represented by the general formula

(I-1), a pharmaceutically acceptable salt thereof or a solvate thereof as an active ingredient.

~~37~~35. An agent for use in suppressing the progression of, suppressing the recurrence of and/or treating cancer or an infectious disease, comprising the compound represented by the general formula (I-1) or a pharmaceutically acceptable salt thereof, as an active ingredient.

~~38~~36. The compound, the pharmaceutically acceptable salt thereof or the solvate thereof, according to claim 1, wherein the compound represented by the general formula (I-1) is (4-(4-(5-acetyl-4-amino-2-fluorophenyl)-3-aminoisoxazolo[4,5-c]pyridin-7-yl)-1H-pyrazol-1-yl)methyl dihydrogen phosphate.

37. The compound, the pharmaceutically acceptable salt thereof or the solvate thereof, according to claim 1 having the following structure, wherein the compound represented by the general formula (I-1) is (4-(4-(5-acetyl-4-amino-2-fluorophenyl)-3-aminoisoxazolo[4,5-c]pyridin-7-yl)-1H-pyrazol-1-yl)methyl dihydrogen phosphate:

